Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis

• Hoofdauteurs: Ana Batalla (Auteur), Hae Jin Suh‐Oh (Auteur), Gregorio Carretero Hernández (Auteur), Javier Miquel‐Miquel (Auteur), Rafael Botella‐Estrada (Auteur), Antonio Martorell‐Calatayud (Auteur), Virginia Sanz‐Motilva (Auteur), Ignasi Figueras‐Nart (Auteur), Angeles Flórez (Auteur)
• Formaat: Boek
• Gepubliceerd in: Wiley, 2023-09-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Background The oral anti‐janus kinase 1 inhibitor upadacitinib has shown a good efficacy-safety profile in the treatment of moderate‐to‐severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far. Objectives To evaluate the effi...